Doxorubicin (generic), Adriamycin, Doxil News

HST Center for Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard-MIT Division of Health Science and Technology, Cambridge, MA 02139, USA 1 Address for correspondence: 65 Landsdowne Street, Partners Research Building, Room # 325, Cambridge, MA 02139, USA E-mail: shiladit@mit.edu Abstract.

Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression.

In this study, we delineated a pathway that involves HER2/PI-3K/Akt in mediating multidrug resistance in human breast cancer cells.

OBJECTIVE:: In patients with hematologic malignancies, chemotherapy can further suppress bone marrow production.

This release is available in French and Spanish . IMAGE: This image shows the effect of gene therapy combined with cytotoxic agents in E spheroids derived from breast cancer cell line MCF-7. A. Control; B. Doxorubicin 10nm, C. Paclitaxel 10nm,... Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the ...

CytRx Corporation , a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric cancer.

Drug resistance is a primary hindrance for the efficiency of chemotherapy against osteosarcoma.

Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection Abstract New strategies to self-assemble biocompatible materials into nanoscale, drug-loaded packages with improved therapeutic efficacy are needed for nanomedicine.

Ziopharm Oncology, Inc. achieved positive data from the multicenter randomized Phase II trial of palifosfamide in patients with unresectable or metastatic soft tissue sarcoma.

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Annual Connective Tissue Oncology Society Meeting taking place in Miami Beach, Florida from November 5 to 7, 2009.

Cancer cells, like bacteria, can develop resistance to drug therapy, leading to relapse of disease.

More than 60% of patients with diffuse large B-cell lymphoma will be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone .

Going smaller could bring better results, especially when it comes to cancer-fighting drugs.

BACKGROUND: The addition of rituximab to CHOP chemotherapy improves outcome in patients with diffuse large B-cell lymphoma .

Tel: +61-03-9479-1517; Fax: +61-03-9479-2467; Email: s.cutts{at}latrobe.edu.au Received July 2, 2009.

Abstract Introduction: The tumour microenvironment is hypoglycaemic, hypoxic and acidotic.

Fax: 585-3945. E-mail: gyost{at}pharm.utah.edu . Received April 18, 2009; accepted August 18, 2009 Abstract Previous work has shown that bioactivation of the cigarette smoke pneumotoxicant 3-methylindole by pulmonary cytochrome P450 enzymes is directly associated with formation of DNA adducts.

A study in the latest issue of the New England Journal of Medicine compares cisplatin with cisplatin plus doxorubicin for standard-risk hepatoblastoma.

Adding doxorubicin to cisplatin for standard-risk hepatoblastoma does not improve resection rates or survival in children with the disease, according to findings from the third study of the International Childhood Liver Tumor Strategy Group .

Giorgio Perilongo, M.D., Rudolf Maibach, Ph.D., Elisabeth Shafford, M.D., Laurence Brugieres, M.D., Penelope Brock, M.D., Bruce Morland, M.D., Beatriz de Camargo, M.D., Jozsef Zsiros, M.D., Derek Roebuck, M.D., Arthur Zimmermann, M.D., Daniel Aronson, M.D., Margaret Childs, Eva Widing, M.D., Veronique Laithier, M.D., Jack Plaschkes, M.D., Jon ...